II. Indications
- Primary Series in the first year of life in the United States
III. Pharmacokinetics
- Oral Tetravalent live virus Vaccine
IV. Preparations
- Rotarix (RV1)
- Monovalent two dose series
- RotaTeq (RV5)
- Pentavalent three dose series
V. Dosing
- Schedule (4 week minimum interval between doses)
- Dose 1: Age 2 months
- First dose must be between ages 6-15 weeks - previously 12 weeks
- Avoid starting series after 15 weeks of age
- Dose 2: Age 4 months
- Dose 3: Age 6 months
- Third dose must be given by 8 months of age
- Third dose is required if RotaTeq was used for any dose, or unknown
- Third dose is not needed if Rotarix (RV1) was given for first two doses
- Dose 1: Age 2 months
- Dose
- Give full vial for each dose (no need to repeat if infant spits up part of dose)
VI. Contraindications
- Immunocompromised infants
- Severe concurrent illness including Gastroenteritis
- History of Intussusception
- Allergy to Vaccine components
VII. Adverse Effects
- Fever after first dose within 3 days
- Adverse effects increase after age 12 months
- Possible association with Kawasaki's Disease
- Increased Incidence of Intussusception
- Most significant with RotaShield Vaccine (Removed from the U.S. market)
- Rotarix and RotaTeq are safer
- Intussusception risk is now minimal (0.79 in 100,000 cases)
- Intussusception typically occurs days 3 to 6 after first Rotavirus Vaccine dose
- References
VIII. Efficacy
- Prevents 50-70% of all Rotavirus cases
- Prevents 70-90% of severe Rotavirus cases
- Seropositive response: 92%
- For every 4 million children immunized against Rotavirus
- Physician visits decrease by 255,000
- Emergency Department visits decrease by 137,000
- Hospitalizations decreased by 44,000
- Deaths decrease by 13
- Cortese (2009) MMWR Recomm Rep 58(RR-2):1-25 [PubMed]
IX. Resources
- CDC Immunization Schedules (last accessed 10/28/2020)
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A viral vaccine that prevents against rotavirus infection, the leading cause of severe acute gastroenteritis. |
Definition (MSH) | Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS. |
Definition (CSP) | vaccines or candidate vaccines used to prevent infection with rotavirus. |
Concepts | Pharmacologic Substance (T121) , Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116) |
MSH | D022243 |
SnomedCT | 116077000, 398866008 |
French | Vaccins contre les rotavirus, Vaccins antirotavirus, Vaccins anti-rotavirus |
Swedish | Rotavirusvacciner |
English | rotavirus vaccine, Rotavirus Vaccines [Chemical/Ingredient], Rotavirus Vaccines, Vaccines, Rotavirus, Rotavirus Vaccine, Rotavirus Vaccine, Live, Oral, Rotavirus vaccine (product), Rotavirus vaccine (substance), Rotavirus vaccine |
Czech | rotaviry - vakcíny |
Finnish | Rotavirusrokotteet |
Russian | ROTAVIRUSNYE VAKTSINY, VAKTSINY ROTAVIRUSNYE, ВАКЦИНЫ РОТАВИРУСНЫЕ, РОТАВИРУСНЫЕ ВАКЦИНЫ |
Japanese | ロタウイルスワクチン, ワクチン-Rotavirus, ワクチン-ロタウイルス |
Italian | Vaccini contro le infezioni da Rotavirus |
Polish | Szczepionki przeciw zakażeniu rotawirusem, Szczepionki przeciw rotawirusom |
Spanish | vacuna contra Rotavirus (sustancia), vacuna contra Rotavirus, vacuna contra rotavirus (producto), vacuna contra rotavirus (sustancia), vacuna contra rotavirus, Vacunas contra Rotavirus |
German | Rotavirusvakzine |
Portuguese | Vacinas contra Rotavirus |
Ontology: RotaShield (C0723145)
Concepts | Pharmacologic Substance (T121) , Immunologic Factor (T129) |
English | RotaShield, rotashield |